window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 22, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

obesity

  • Clinical & Regulatory,Drug Delivery & Formulation,Pharmaceuticals and therapeutics,Research & Development

    Rani reports positive Phase 1 data for oral obesity therapy RT-114

    Rani Therapeutics has reported positive initial Phase 1a data for [...]

    July 16, 2026
  • Clinical & Regulatory,Medical devices,Pharmaceuticals and therapeutics,Research & Development

    Revita maintains GLP-1 weight loss one year after treatment discontinuation in REMAIN-1 trial

    Fractyl Health has reported positive one-year data from the midpoint [...]

    July 16, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    Resalis doses first participant in Phase 1b obesity trial

    Resalis Therapeutics has dosed the first participant in a Phase [...]

    June 30, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Delivery & Formulation,Drug Discovery & Development,Therapeutic Areas

    Nanexa targets next-generation ‘fat jab’ with monthly semaglutide delivery platform

    Sweden-based Nanexa has reported preclinical data for a long-acting semaglutide [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development

    Confo Therapeutics secures VLAIO grant to develop ultra-long-acting GPCR antibody therapies

    Confo Therapeutics has been awarded a EUR 1 million grant [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Skye Bioscience Phase 2a data show added weight loss with nimacimab–semaglutide combination

    Skye Bioscience has reported topline results from its Phase 2a [...]

    May 5, 2026
  • Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    New Phesi data shows more than 100 diseases being studied with GLP-1 therapies

    Analysis highlights potential for benefits far beyond obesity, signalling a [...]

    May 5, 2026
  • Opinion & Events,Pharmaceuticals and therapeutics,Therapeutic Areas

    Imperial College London centre expands endocrine care as UAE approves GLP-1 therapies

    Imperial College London Diabetes & Endocrine Centre (ICLDEC) has expanded [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development

    Corteria advances CRF2 agonist programs in heart failure and obesity

    Corteria Pharmaceuticals has launched a Phase 2 trial of its [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Opinion & Events

    Ciloa lands €6.5 million (£5.7 million) government backing to develop novel obesity and diabetes bio-drug

    Ciloa, a pioneer in bioengineering extracellular vesicles (EVs) for innovative [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Adneuris licenses Phase 3 pain therapy cebranopadol to Conba for Greater China
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics
  • Latent Labs opens lab-validated AI drug design platform to researchers worldwide
    Categories: Digital & Data, Drug Discovery & Development, Research & Development
  • PET imaging reveals widespread synaptic loss in schizophrenia
    Categories: Clinical & Regulatory, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top